4CPS-133 Response to vemurafenib-cobimetinib with reduced doses in a patient with metastasic melanoma: concerning a case

BACKGROUND: Melanoma is the cutaneous tumour with the highest mortality. BRAF inhibitors are indicated for patients with metastatic melanoma and are part of the first-line treatment of this disease. PURPOSE: To describe the clinical course of a patient diagnosed with metastatic melanoma who develope...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Hosp Pharm
Egile Nagusiak: Santana, E Ramos, Romero, MM Viña, Rojas, S Hernández, Linares, S Ramos, Dávila, M Navarro, Alonso, J Merino, Nicolás, F Gutiérrez
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 2018
Gaiak:
Section 4: Clinical pharmacy services
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535375/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.224
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak